临床医学工程
臨床醫學工程
림상의학공정
CLINICAL MEDICAL ENGINEERING
2014年
5期
571-572,575
,共3页
凝血酶%奥美拉唑%胃出血%疗效%安全性
凝血酶%奧美拉唑%胃齣血%療效%安全性
응혈매%오미랍서%위출혈%료효%안전성
Thrombin%Omeprazole%Gastrorrhagia%Clinical effect%Safety
目的:观察凝血酶联合奥美拉唑治疗胃出血的疗效及安全性。方法选择70例胃出血患者,根据治疗方案不同分为两组各35例,观察组治疗上给予凝血酶联合奥美拉唑,对照组治疗上单用凝血酶。观察两组患者治疗总有效率、大便隐血转阴时间、平均住院时间等。此外,对两组患者治疗期间各类不良反应进行记录。结果观察组治疗总有效率为97.14豫,高于对照组的77.14豫,差异有显著性(孕<0.05);观察组大便隐血转阴时间、平均住院时间与对照组比较,有明显缩短,差异均有显著性(孕<0.05);治疗期间观察组不良反应发生率为2.86豫,低于对照组的22.86豫,差异有显著性(孕<0.05)。结论凝血酶联合奥美拉唑治疗胃出血,疗效可靠,能够较短时间内止血,缩短住院时间,减轻患者经济压力。此外,不良反应较少,值得临床推广。
目的:觀察凝血酶聯閤奧美拉唑治療胃齣血的療效及安全性。方法選擇70例胃齣血患者,根據治療方案不同分為兩組各35例,觀察組治療上給予凝血酶聯閤奧美拉唑,對照組治療上單用凝血酶。觀察兩組患者治療總有效率、大便隱血轉陰時間、平均住院時間等。此外,對兩組患者治療期間各類不良反應進行記錄。結果觀察組治療總有效率為97.14豫,高于對照組的77.14豫,差異有顯著性(孕<0.05);觀察組大便隱血轉陰時間、平均住院時間與對照組比較,有明顯縮短,差異均有顯著性(孕<0.05);治療期間觀察組不良反應髮生率為2.86豫,低于對照組的22.86豫,差異有顯著性(孕<0.05)。結論凝血酶聯閤奧美拉唑治療胃齣血,療效可靠,能夠較短時間內止血,縮短住院時間,減輕患者經濟壓力。此外,不良反應較少,值得臨床推廣。
목적:관찰응혈매연합오미랍서치료위출혈적료효급안전성。방법선택70례위출혈환자,근거치료방안불동분위량조각35례,관찰조치료상급여응혈매연합오미랍서,대조조치료상단용응혈매。관찰량조환자치료총유효솔、대편은혈전음시간、평균주원시간등。차외,대량조환자치료기간각류불량반응진행기록。결과관찰조치료총유효솔위97.14예,고우대조조적77.14예,차이유현저성(잉<0.05);관찰조대편은혈전음시간、평균주원시간여대조조비교,유명현축단,차이균유현저성(잉<0.05);치료기간관찰조불량반응발생솔위2.86예,저우대조조적22.86예,차이유현저성(잉<0.05)。결론응혈매연합오미랍서치료위출혈,료효가고,능구교단시간내지혈,축단주원시간,감경환자경제압력。차외,불량반응교소,치득림상추엄。
Objective To observe the clinical effect and safety of thrombin combined with omeprazole in the treatment of gastrorrhagia. Methods 70 patients with gastrorrhagia were randomly divided into two groups, with 35 cases in each group. The observation group was treated with thrombin combined with omeprazole, while the control group was treated with thrombin alone. The total effective rate, FOBT negative time, average hospital stays and adverse reactions during therapy were observed. Results The total effective rate of observation group was 97.14%, significantly higher than 77.14%of control group (P<0.05);The FOBT negative time and average hospital stays of observation group were significantly shorter than those of control group (both P<0.05);During treatment, the incidence of adverse reactions of observation group was 2.86%, significantly lower than 22.86%of control group (P<0.05). Conclusions Thrombin combined with omeprazole has an accurate clinical effect for the treatment of gastrorrhagia. It can stop bleeding in a short time, shorten hospital stays, and relieve economic burdens of patients. Besides, it has few adverse reactions, so it is worthy of clinical application.